CLAIMS

~~1. A combination product comprising:~~

~~(i) Elafibranor (ELA) or a pharmaceutically acceptable salt thereof; and~~

~~(ii) a FXR agonist selected from the group consisting of obeticholic acid (OCA), a pharmaceutically acceptable salt of OCA, INT-767 and a pharmaceutically acceptable salt of INT-767.~~

~~2. The combination product according to claim 1, wherein the FXR agonist is Obeticholic acid (OCA) or a pharmaceutically acceptable salt thereof.~~

~~3. The combination product according to claim 1, wherein the FXR agonist is INT-767 or a pharmaceutically acceptable salt thereof.~~

~~4. The combination product according to any one of claims 1 to 3, wherein the combination product is a composition comprising (i) and (ii) and a pharmaceutically acceptable carrier.~~

~~5. The combination product according to any one of claims 1 to 3, wherein the combination product is a kit of parts comprising (i) and (ii).~~

~~6. The combination product according to any one of claims 1 to 5, for sequential, separate or simultaneous use in the treatment of a disease.~~

~~7~~1. Use of:

(i) Elafibranor (ELA) or a pharmaceutically acceptable salt thereof; and

(ii) a FXR agonist selected from the group consisting of obeticholic acid (OCA), a pharmaceutically acceptable salt of OCA, INT-767 and a pharmaceutically acceptable salt of INT-767,

in the preparation of a medicament for combination therapy for the treatment of an immune, inflammatory, metabolic, fibrotic or cholestatic disease, wherein the disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

~~8. The use according to claim 7, wherein the disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).~~

~~9~~2. The use according to claim ~~7 or 8~~1, wherein the FXR agonist is Obeticholic acid (OCA) or a pharmaceutically acceptable salt thereof; and wherein:

- ELA is for administration at a dose comprised between 5 and 80 mg/day and OCA is for administration at a dose comprised between 7 and 17 mg/day;
- ELA is for administration at a dose comprised between 40 and 60 mg/day and OCA is for administration at a dose comprised between 5 and 12.5 mg/day;
- ELA is for administration at a dose comprised between 32 and 48 mg/day and OCA is for administration at a dose comprised between 4 and 10 mg/day;
- ELA is for administration at a dose comprised between 27 and 40 mg/day and OCA is for administration at a dose comprised between 3 and 8 mg/day;
- ELA is for administration at a dose comprised between 16 and 24 mg/day and OCA is for administration at a dose comprised between 2 and 5 mg/day; or
- ELA is for administration at a dose comprised between 8 and 12 mg/day and OCA is for administration at a dose comprised between 1 and 2.5 mg/day.

~~10~~3. Use according to ~~any one of claims 7 to 9~~claim 1 or 2, wherein (i) and (ii) are for separate, sequential or simultaneous administration.